| Поле DC | Значение | Язык |
|---|
| dc.contributor.author | Soldatov, V. O. | - |
| dc.contributor.author | Kubekina, M. V. | - |
| dc.contributor.author | Silaeva, Yu. Yu. | - |
| dc.contributor.author | Bruter, A. V. | - |
| dc.contributor.author | Deykin, A. V. | - |
| dc.date.accessioned | 2022-05-04T12:58:02Z | - |
| dc.date.available | 2022-05-04T12:58:02Z | - |
| dc.date.issued | 2020 | - |
| dc.identifier.citation | On the way from SARS-CoV-sensitive mice to murine COVID-19 model / V.O. Soldatov [et al.] // Research Results in Pharmacology. - 2020. - Vol.6, №2.-P. 1-7. - Doi: 10.3897/rrpharmacology.6.53633 | ru |
| dc.identifier.uri | http://dspace.bsu.edu.ru/handle/123456789/46585 | - |
| dc.description.abstract | The coronavirus disease 2019 (COVID-19) is a master killer which appeared suddenly and which has already claimed more than 200,000 human lives. In this situation, laboratories are in urgent need for a COVID-19 murine model to search for effective antiviral compounds | ru |
| dc.language.iso | en | ru |
| dc.subject | medicine | ru |
| dc.subject | pharmacology | ru |
| dc.subject | antiviral agents | ru |
| dc.subject | COVID-19 | ru |
| dc.subject | SARS-CoV-2 | ru |
| dc.subject | ACE2 | ru |
| dc.subject | TMPRSS2 | ru |
| dc.subject | mice | ru |
| dc.subject | CRISPR/Cas9 | ru |
| dc.subject | viral sensitivity | ru |
| dc.title | On the way from SARS-CoV-sensitive mice to murine COVID-19 model | ru |
| dc.type | Article | ru |
| Располагается в коллекциях: | Vol. 6, № 2
|
